PubRank

Rosemarie Mick

Author PubWeight™ 94.71‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007 4.95
2 Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol 2007 3.68
3 An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 2003 3.21
4 Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 2012 3.15
5 Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007 2.25
6 CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med 2012 2.22
7 Transcervical thymectomy for myasthenia gravis achieves results comparable to thymectomy by sternotomy. Ann Thorac Surg 2002 2.15
8 Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002 2.05
9 Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread. J Clin Oncol 2004 1.93
10 HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 2005 1.81
11 Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma. Ann Thorac Surg 2011 1.80
12 Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 2003 1.70
13 Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 2003 1.68
14 A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg 2003 1.66
15 Clinical trial resources on the internet must be designed to reach underrepresented minorities. Cancer J 2007 1.56
16 Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome. Int J Radiat Oncol Biol Phys 2007 1.55
17 Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 2003 1.50
18 Patient initiation of complementary and alternative medical therapies (CAM) following cancer diagnosis. Cancer J 2007 1.50
19 Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res 2007 1.47
20 Utility of the systemic inflammatory response syndrome (SIRS) criteria in predicting the onset of septic shock in hospitalized patients with hematologic malignancies. Cancer Biol Ther 2009 1.40
21 Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg 2012 1.39
22 Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One 2009 1.37
23 A phase I study of topical Tempol for the prevention of alopecia induced by whole brain radiotherapy. Clin Cancer Res 2004 1.37
24 Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013 1.37
25 Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 2003 1.35
26 Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 2003 1.34
27 Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res 2008 1.26
28 Skin-sparing mastectomy and immediate reconstruction is an acceptable treatment option for patients with high-risk breast carcinoma. Cancer 2005 1.22
29 Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J Environ Pathol Toxicol Oncol 2006 1.21
30 A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res 2006 1.19
31 HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 2012 1.18
32 Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2013 1.16
33 Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? Lung Cancer 2013 1.16
34 A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials. Clin Trials 2012 1.10
35 Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med 2009 1.09
36 Proceedings of the University of Pennsylvania annual conference on statistical issues in clinical trials: early, translational and proof of concept studies: the 'go/no go' decisions. Stat Med 2010 1.08
37 Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res 2007 1.08
38 Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer. Cancer Immunol Immunother 2009 1.07
39 A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response. J Thorac Oncol 2012 1.04
40 Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am J Hematol 2013 1.02
41 A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother 2012 1.02
42 Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). J Immunol 2004 1.02
43 EF5 binding and clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2006 1.01
44 A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 2013 1.01
45 Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res 2009 1.00
46 A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J Transl Med 2013 0.99
47 Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses. PLoS One 2011 0.97
48 Signaling pathways in NSCLC as a predictor of outcome and response to therapy. Lung 2004 0.93
49 Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies. Clin Lung Cancer 2013 0.93
50 c-Met expression in tall cell variant papillary carcinoma of the thyroid. Cancer 2003 0.92
51 Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer. Ann Surg Oncol 2002 0.91
52 Dysphagia after chemoradiation: analysis by modified barium swallow. Ann Otol Rhinol Laryngol 2007 0.90
53 Mannose binding lectin (MBL) polymorphisms associated with low MBL production in patients with dermatomyositis. J Invest Dermatol 2002 0.89
54 Progression-free survival ratio as end point for phase II trials in advanced solid tumors. J Clin Oncol 2011 0.89
55 Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma. Am J Pathol 2002 0.89
56 Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response. Cancer Lett 2007 0.89
57 Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS. Ann Surg Oncol 2013 0.88
58 Immunohistochemical method identifies lymphovascular invasion in a majority of oral squamous cell carcinomas and discriminates between blood and lymphatic vessel invasion. J Histochem Cytochem 2008 0.87
59 Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood 2002 0.87
60 A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer. Cancer 2014 0.86
61 Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. Clin Cancer Res 2004 0.84
62 The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease. J Surg Oncol 2011 0.84
63 Prediction of difficult laryngoscopy: does obesity play a role? Ann Otol Rhinol Laryngol 2007 0.84
64 Thioredoxin reductase-1 mediates curcumin-induced radiosensitization of squamous carcinoma cells. Cancer Res 2010 0.83
65 Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantation. J Hematother Stem Cell Res 2003 0.82
66 Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma. JOP 2011 0.81
67 Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival. Prostate 2005 0.81
68 Comparison of hindlimb unloading and partial weight suspension models for spaceflight-type condition induced effects on white blood cells. Adv Space Res 2012 0.80
69 Use of radiotracer for sentinel lymph node mapping in breast cancer optimizes staging independent of site of administration. Clin Nucl Med 2006 0.79
70 Serum antibodies to EpCAM in healthy donors but not ulcerative colitis patients. Cancer Immunol Immunother 2005 0.78
71 Intraperitoneal photodynamic therapy causes a capillary-leak syndrome. Ann Surg Oncol 2003 0.77
72 Daily isocenter correction with electromagnetic-based localization improves target coverage and rectal sparing during prostate radiotherapy. Int J Radiat Oncol Biol Phys 2009 0.76
73 Clinical application of positron emission tomography in designing radiation fields in non-small cell lung cancer patients. Exp Ther Med 2010 0.75